[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-370614-105":59,"doc-detail-370614-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-impact-of-renin-angiotensin-system-inhibitors-on-colorectal-neoplasm-development","The impact of renin-angiotensin system inhibitors on colorectal neoplasm development","","Renin-angiotensin system (RAS) inhibitors may provide chemopreventive benefit against colorectal cancer (CRC), yet their effect on colorectal precancerous lesions remains unclear. This study combined preclinical mouse models and retrospective clinical analyses, evaluating enalapril or RAS inhibitor use of at least 1 year. RAS inhibition reduced tumor burden and volume in experiments and was associated with fewer incidental and recurrent colorectal neoplasms during follow-up.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-impact-of-renin-angiotensin-system-inhibitors-on-colorectal-neoplasm-development/370614/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-impact-of-renin-angiotensin-system-inhibitors-on-colorectal-neoplasm-development/370614.png","ImageObject",300,407,{"name":92,"@type":93},"Sarah ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What question does the study investigate about RAS inhibitors?","Question",{"text":112,"@type":113},"It examines whether RAS inhibitors affect the risk of colorectal precancerous lesions and neoplasms, not just colorectal cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were outcomes assessed in the preclinical and clinical parts of the study?",{"text":117,"@type":113},"Preclinically, mouse models measured body weight, colon length, and tumor size. Clinically, researchers evaluated incidental and recurrent colorectal neoplasms from index and follow-up colonoscopies.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main results regarding colorectal neoplasm risk during follow-up?",{"text":121,"@type":113},"During follow-up, incidental and recurrent colorectal neoplasms were less common in the RAS inhibitor group than in other anti-hypertensives. In the follow-up cohort, hypertension increased risk, while RAS inhibitor use was linked to a lower risk.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},370614,1790812817,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},962085320529,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Clin Hypertens. 2025 Jun 1;31:e22 [https://doi.org/10.5646/ch.2025.31.e22](https://doi.org/10.5646/ch.2025.31.e22)[ ](https://doi.org/10.5646/ch.2025.31.e22)eISSN 2056-5909  \nResearch Article  \nReceived: Feb 23, 2025  \nRevised: Apr 9, 2025  \nAccepted: Apr 30, 2025  \nPublished online: Jun 1, 2025  \n*Correspondence:  \nHeesun Lee  \nDivision of Cardiology, Department of Internal Medicine, Seoul National University Hospital Healthcare System Gangnam Centre, 152 Teheran-ro, Gangnam-gu, Seoul 06236, Republic of Korea.  \n[Email: md.sunny.lee@gmail.com](Email: md.sunny.lee@gmail.com)[ ](Email: md.sunny.lee@gmail.com)[65847@snuh.org](65847@snuh.org)  \n†Yoo Min Han and Ji Min Choi contributed equally to this work as first authors.  \nCopyright © 2025 The Korean Society of Hypertension  \nIt is identical to the Creative Commons Attribution Non-Commercial License ([https://](https://)[ ](https://)[creativecommons.org/licenses/by-nc/4.0/](creativecommons.org/licenses/by-nc/4.0/)) .  \nORCID iDs  \nYoo Min Han  [https://orcid.org/0000-0001-5580-8427](https://orcid.org/0000-0001-5580-8427)[ ](https://orcid.org/0000-0001-5580-8427)Ji Min Choi  [https://orcid.org/0000-0001-8611-4647](https://orcid.org/0000-0001-8611-4647)[ ](https://orcid.org/0000-0001-8611-4647)Tae-Min Rhee  [https://orcid.org/0000-0002-0504-0736](https://orcid.org/0000-0002-0504-0736)[ ](https://orcid.org/0000-0002-0504-0736)Su-Yeon Choi  [https://orcid.org/0000-0001-9977-4740](https://orcid.org/0000-0001-9977-4740)[ ](https://orcid.org/0000-0001-9977-4740)Heesun Lee  [https://orcid.org/0000-0003-4037-3955](https://orcid.org/0000-0003-4037-3955)  \n[https://clinicalhypertension.org](https://clinicalhypertension.org)  \nThe impact of renin-angiotensin system inhibitors on colorectal neoplasm development  \nYoo Min Han  1†, Ji Min Choi  1†, Tae-Min Rhee  2, Su-Yeon Choi  2, and Heesun Lee  2*  \n1Division of Gastroenterology, Department of Internal Medicine, Seoul National University Hospital Healthcare System Gangnam Centre, Seoul, Republic of Korea  \n2Division of Cardiology, Department of Internal Medicine, Seoul National University Hospital Healthcare System Gangnam Centre, Seoul, Republic of Korea  \nABSTRACT  \nBackground: Renin-angiotensin system (RAS) inhibitors have shown potential chemopreventive effects against colorectal cancer (CRC). However, little is known about the impact of RAS inhibitors on the risk of colorectal precancerous lesions.  \nMethods: Preclinically, we established mouse models of colitis-associated colon cancer and xenografts: vehicle, 1 mg/kg, 5 mg/kg enalapril groups. Body weight, colon length, and colorectal tumor size were evaluated on the euthanization day. Clinically, we retrospectively recruited 8,388 asymptomatic adults undergoing their first-ever colonoscopy for health check-ups (index cohort). From the index cohort, we selected individuals undergoing follow-up colonoscopy (follow-up cohort). The study outcome was incidental and recurrent colorectal neoplasms, including CRC. We evaluated the prevalence and risk of colorectal neoplasms associated with RAS inhibitor use of ≥ 1 year.  \nResults: In the experimental study, enalapril administration significantly attenuated weight loss and colon shortening, reduced tumor numbers in colitis-associated colon cancer models, and decreased tumor volume in the xenografts. In the index cohort, while the initial analysis showed a positive association with the RAS inhibitor use (unadjusted odds ratio [OR], 1.22), this shifted toward an inverse trend after adjusting for confounders (adjusted OR, 0.91) . During follow-up (median, 41.0 months), incidental and recurrent colorectal neoplasms were less common in the RAS inhibitor group (32.6%) than in the other anti-hypertensives group (39.1%) (P \u003C 0.001), despite similar intervals between the index and follow-up endoscopies. In the follow-up cohort, hypertension itself was a risk factor for colorectal neoplasm development (adjusted hazard ratio [HR], 1.70; 95% confidence ","cbCaih3hm9MZQYnC","https://ap.wps.com/l/cbCaih3hm9MZQYnC","pdf",1899516,12,"English","# Abstract\n# Background\n# Methods\n## Preclinical models\n## Clinical cohort and outcomes\n# Results\n# Conclusions\n# Keywords","[{\"question\":\"What question does the study investigate about RAS inhibitors?\",\"answer\":\"It examines whether RAS inhibitors affect the risk of colorectal precancerous lesions and neoplasms, not just colorectal cancer.\"},{\"question\":\"How were outcomes assessed in the preclinical and clinical parts of the study?\",\"answer\":\"Preclinically, mouse models measured body weight, colon length, and tumor size. Clinically, researchers evaluated incidental and recurrent colorectal neoplasms from index and follow-up colonoscopies.\"},{\"question\":\"What were the main results regarding colorectal neoplasm risk during follow-up?\",\"answer\":\"During follow-up, incidental and recurrent colorectal neoplasms were less common in the RAS inhibitor group than in other anti-hypertensives. In the follow-up cohort, hypertension increased risk, while RAS inhibitor use was linked to a lower risk.\"}]","The impact of renin-angiotensin system inhibitors on colorectal neoplasm development | PDF",1790189471,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aa623efdc49b7a5d5cced474647f20cc.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7e4d1bff7987e013f66485f612802e08.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/595b72c8eb01b906c775e5001bd81d8e.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1a69cfc7cfc742aafc70c61052f2b7e5.webp",980,1306]